Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teduglutide safety in Japanese pediatric SBS
NCT05027308Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2022
- Primary completion
- Sep 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of teduglutide in short bowel syndrome (SBS), sponsored by Takeda. Started Jan 2022; status: completed.
02
Drugs
teduglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT05027308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027308.